TY - JOUR
T1 - Beyond bevacizumab
T2 - Investigating new angiogenesis inhibitors in ovarian cancer
AU - Tomao, Federica
AU - Papa, Anselmo
AU - Rossi, Luigi
AU - Caruso, Davide
AU - Zoratto, Federica
AU - Benedetti Panici, Pierluigi
AU - Tomao, Silverio
PY - 2014/1
Y1 - 2014/1
N2 - Introduction: Ovarian cancer is the most lethal gynecological cancer, mainly because of the advanced stage of the disease at diagnosis, with recent research investigating novel targets and agents into the clinical practice, with the aim to improve prognosis and quality of life. Angiogenesis is a significant target for ovarian cancer therapy. Areas covered: Areas covered in this review include the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in ovarian cancer patients. These therapeutic strategies comprise monoclonal antibodies and tyrosine kinase inhibitors. These drugs have as molecular targets such as vascular endothelial growth factor (VEGF), VEGF receptor, platelet-derived growth factor, fibroblast growth factor, angiopoietin and Ephrin type-A receptor 2. Expert opinion: The expansion in understanding the molecular biology that characterizes cancer cells has led to the rapid development of new agents to target important pathways, but the heterogeneity of ovarian cancer biology indicates that there is no predominant defect. This review attempts to discuss progress till date in tackling a more general target applicable to ovarian cancer angiogenesis.
AB - Introduction: Ovarian cancer is the most lethal gynecological cancer, mainly because of the advanced stage of the disease at diagnosis, with recent research investigating novel targets and agents into the clinical practice, with the aim to improve prognosis and quality of life. Angiogenesis is a significant target for ovarian cancer therapy. Areas covered: Areas covered in this review include the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in ovarian cancer patients. These therapeutic strategies comprise monoclonal antibodies and tyrosine kinase inhibitors. These drugs have as molecular targets such as vascular endothelial growth factor (VEGF), VEGF receptor, platelet-derived growth factor, fibroblast growth factor, angiopoietin and Ephrin type-A receptor 2. Expert opinion: The expansion in understanding the molecular biology that characterizes cancer cells has led to the rapid development of new agents to target important pathways, but the heterogeneity of ovarian cancer biology indicates that there is no predominant defect. This review attempts to discuss progress till date in tackling a more general target applicable to ovarian cancer angiogenesis.
KW - Aflibercept
KW - Angiogenesis
KW - Bevacizumab
KW - Chemotherapy
KW - Epithelial ovarian cancer
KW - Tyrosine kinase inhibitors
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=84889783720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84889783720&partnerID=8YFLogxK
U2 - 10.1517/13543784.2013.839657
DO - 10.1517/13543784.2013.839657
M3 - Article
C2 - 24111925
AN - SCOPUS:84889783720
VL - 23
SP - 37
EP - 53
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
SN - 1354-3784
IS - 1
ER -